Immune-Mediated Therapies in Lymphoma

被引：1

作者：

Forbes, Sheryl G. ^{[1
]}

Mistry, Haleigh E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA

来源：

SEMINARS IN ONCOLOGY NURSING | 2019年 / 35卷 / 05期

关键词：

Non-Hodgkin lymphoma; Hodgkin lymphoma; Immune-mediated therapy; Monoclonal antibody; Checkpoint inhibitors; PI3 kinase inhibitors; Immune modulators; Bruton's tyrosine kinase inhibitors; BCL-2; inhibitors; CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; HODGKIN; MANAGEMENT; NIVOLUMAB; MULTICOHORT; VENETOCLAX; FAILURE;

D O I：

10.1016/j.soncn.2019.08.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To review types of lymphoma, risk factors, and evaluate novel immune-mediated therapies, including side effects and management of immune-mediated toxicities. Data Source: Published literature, national statistics, and Web sites. Conclusion: Novel biologic agents are being developed with the potential to improve outcomes. However, these novel agents pose unique and sometimes serious adverse events. Implications for Nursing Practice: The immune-mediated adverse events require a multidisciplinary approach and early identification. It is imperative providers and nurses are educated on the management of the unique toxicities caused by lymphoma treatment. (C) 2019 Elsevier Inc. All rights reserved.

引用

页数：6

共 22 条

[1] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Armand, Philippe
Engert, Andreas
Younes, Anas
Fanale, Michelle
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John M.
Collins, Graham P.
Ramchandren, Radhakrishnan
Cohen, Jonathon B.
De Boer, Jan Paul
Kuruvilla, John
Savage, Kerry J.
Trneny, Marek
Shipp, Margaret A.
Kato, Kazunobu
Sumbul, Anne
Farsaci, Benedetto
Ansell, Stephen M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) : 1428 - +
[2] Non-Hodgkin lymphoma
Armitage, James O.
Gascoyne, Randy D.
Lunning, Matthew A.
Cavalli, Franco
[J]. LANCET, 2017, 390 (10091) : 298 - 310
[3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, Julie R.
Lacchetti, Christina
Schneider, Bryan J.
Atkins, Michael B.
Brassil, Kelly J.
Caterino, Jeffrey M.
Chau, Ian
Ernstoff, Marc S.
Gardner, Jennifer M.
Ginex, Pamela
Hallmeyer, Sigrun
Chakrabarty, Jennifer Holter
Leighl, Natasha B.
Mammen, Jennifer S.
McDermott, David F.
Naing, Aung
Nastoupil, Loretta J.
Phillips, Tanyanika
Porter, Laura D.
Puzanov, Igor
Reichner, Cristina A.
Santomasso, Bianca D.
Seigel, Carole
Spira, Alexander
Suarez-Almazor, Maria E.
Wang, Yinghong
Weber, Jeffrey S.
Wolchok, Jedd D.
Thompson, John A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
[4] Novel CD20 monoclonal antibodies for lymphoma therapy
Cang, Shundong
Mukhi, Nikhil
Wang, Kemeng
Liu, Delong
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
[5] Novel agents for relapsed and refractory follicular lymphoma
Cheah, Chan Yoon
Fowler, Nathan H.
[J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (01) : 41 - 48
[6] Idelalisib in the management of lymphoma
Cheah, Chan Yoon
Fowler, Nathan H.
[J]. BLOOD, 2016, 128 (03) : 331 - 336
[7] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Chen, Robert
Zinzani, Pier Luigi
Fanale, Michelle A.
Armand, Philippe
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Zhang, Yinghua
Ricart, Alejandro D.
Balakumaran, Arun
Moskowitz, Craig H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2125 - +
[8] Colevas AD, 2004, J CLIN ONCOL, V22, p543S
[9] Columbus G, 2019, FDA GRANTS UMBRALISI
[10] Venetoclax: First Global Approval
Deeks, Emma D.
[J]. DRUGS, 2016, 76 (09) : 979 - 987

← 1 2 3 →